<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204655">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000317</url>
  </required_header>
  <id_info>
    <org_study_id>#3124</org_study_id>
    <secondary_id>R01DA009582</secondary_id>
    <secondary_id>R01-09582-1</secondary_id>
    <nct_id>NCT00000317</nct_id>
  </id_info>
  <brief_title>Early Phase II Trials for Cocaine Medication Development - 1</brief_title>
  <official_title>Early Phase II Trials for Cocaine Medication Development</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Research Foundation for Mental Hygiene, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop models for early Phase II testing of potential
      medications for cocaine dependence: amoxapine, risperidone and other agents.

      The study was a controlled pilot trial of risperidone in opiate-dependent patients on
      methadone maintenance. The study explored whether risperidone reduced cocaine use, cocaine
      craving, and cocaine subjective effects in patients on methadone maintenance who abused
      cocaine and whether it had an acceptable side effect profile. This
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an 18-week prospective, randomized, placebo-controlled crossover design with
      placebo lead-in phase and terminal placebo phase. After two weeks of single-blind placebo,
      patients were randomly assigned to one of two schedules of medication:

      2 Week Baseline Weeks 1-6 Weeks 7-12 Weeks 13-18 Group 1 placebo risperidone placebo placebo
      Group 2 placebo placebo risperidone placebo

      The first 6-week phase provided an initial double-blind medication-placebo comparison. In
      the second six-week phase (weeks 7-12), patients crossed over to the opposite treatment.
      During weeks 13-18, Group 1 patients remained on placebo while Group 2 patients were tapered
      from risperidone to placebo. For six weeks after the end of the trial, patients were offered
      routine clinical treatment with counseling and psychiatrist visits as needed. Medication
      dosage was titrated upwards on a fixed-flexible schedule to a maximum dose of 4 mg per day.
      Medication began at Â½ mg risperidone for 3 days, then 1 mg for four days, 2 mg per day
      during week 2, 3 mg per day during week 3, and 4 mg per day during weeks 4-6. The titration
      schedule for risperidone in weeks 7-12 was the same as for weeks 1-6. In addition to
      treatment as usual, patients received a modified manual-guided relapse prevention counseling
      program in weekly meetings lasting approximately 20 minutes; these sessions provided
      cognitive and behavioral skills that were found to be helpful to patients in reducing
      cocaine use.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1996</start_date>
  <completion_date type="Actual">July 1999</completion_date>
  <primary_completion_date type="Actual">July 1999</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Side effects</measure>
    <time_frame>1x/week for 18 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Using the Modified Systemic Assessment for Treatment Emergent Effects the psychiatrist assessed side effects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Craving</measure>
    <time_frame>3x/week during 18 weeks of trial</time_frame>
    <safety_issue>No</safety_issue>
    <description>subjective cravings were recorded on the Cocaine craving scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug use</measure>
    <time_frame>3x/week during 18 weeks of trial</time_frame>
    <safety_issue>No</safety_issue>
    <description>urine drug testing and self reported use on the Substance Use Weekly Inventory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retention</measure>
    <time_frame>18 weeks or length of study participation</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Cocaine-Related Disorders</condition>
  <condition>Substance-Related Disorders</condition>
  <arm_group>
    <arm_group_label>PLacebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus relapse prevention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Risperidone (4mg/day)plus relapse prevention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Risperidone (4mg/day)</description>
    <arm_group_label>Risperidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>PLacebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Relapse prevention counseling</intervention_name>
    <description>Modified manual guided relapse prevention counseling. Weekly 20 minute sessions consisting of cognitive behavioral skills.</description>
    <arm_group_label>PLacebo</arm_group_label>
    <arm_group_label>Risperidone</arm_group_label>
    <other_name>RPT-CBT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          1. good standing at methadone maintenance program

          2. DSM-IV criteria for cocaine dependence or abuse

          3. used cocaine at least 4 times in last month

          4. able to give informed consent

        Exclusion criteria

          1. currently meets DSM-IV criteria for Major depression or dysthymia

          2. meets DSM-IV criteria for attention deficit hyperactivity disorder, bipolar disorder,
             schizophrenia or any psychotic disorder

          3. history of seizures

          4. history of allergic reaction to risperidone

          5. chronic organic mental disorder

          6. significant current suicidal risk

          7. pregnancy, lactation or failure to use adequate birth control (for females)

          8. unstable physical disorders that may make participation hazardous

          9. coronary vascular disease

         10. cardiac conduction system disease as indicated by QRS duration &gt;/= 0.11

         11. current use of other prescribed psychotropic medications

         12. history of failure to respond to a previous adequate trial of risperidone

         13. history of neuroleptic malignant syndrome, tardive dyskinesia, or severe
             extrapyramidal reactions to neuroleptic medications

         14. current DSM-IV criteria for another substance dependence other than nicotine.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Nunes, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Foundation for Mental Hygiene, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Foundation for Mental Hygiene</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 24, 2012</lastchanged_date>
  <firstreceived_date>September 20, 1999</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
